Alvarez & Marsal Managing Director Mark Freitas was featured among Top 25 Life Sciences Consultants and Leaders of 2024
The Consulting Report is pleased to announce The Top 25 Life Sciences Consultants and Leaders of 2024. The life sciences industry has undergone significant transformation in recent years, fueled by scientific breakthroughs, technological innovation, and the global impact of the COVID-19 pandemic. While these shifts have ushered in new opportunities for patient care, drug development, and medical innovation, they have also presented complex challenges. Life sciences organizations now face increased pressure to optimize pricing, navigate unpredictable market access, adapt to changing consumer behavior, and enhance operational efficiency.
Mark Freitas specializes in helping businesses reach their full potential by developing successful strategies that maximize growth while avoiding operational challenges. His expertise spans corporate finance and operations, strategic planning, board governance, mergers and acquisitions activity, risk management, and compliance.
Read the Full Article Here
What if the biosimilar wave is just a ripple?
September 9, 2025
As biologics face a record-breaking patent cliff, the anticipated biosimilar wave may be more of a ripple than a wave. To thrive, life sciences firms must shift from solely pursuing speed to mastering precision.
ALVAREZ & MARSAL BOLSTERS ITS HEALTHCARE PRACTICE IN SOUTHEAST ASIA (ASEAN) REGION WITH THE APPOINTMENT OF SANATH KUMAR AS MANAGING DIRECTOR
September 1, 2025
Leading global professional services firm Alvarez & Marsal (A&M) has announced the appointment of Sanath Kumar as Managing Director within its Southeast Asia and Australia (SEAA) business unit. Based in Singapore, Mr. Sanath will play a strategic role in building out A&M’s Healthcare and Life Sciences practice across ASEAN markets.
Next-Generation Antibodies: A New Era in Immuno-Oncology
August 25, 2025
As the immune checkpoint inhibitor (ICI) market nears a patent cliff, the $50B immuno-oncology (IO) field is now seeking to surpass the limitations of earlier ICIs by enhancing survival outcomes, broadening coverage, and overcoming resistance mechanisms.
Strategic Patience in GenAI - A smarter path to AI leadership
August 11, 2025
As Generative AI accelerates across industries, life sciences firms must seek to adopt strategic patience, prioritizing long-term enterprise value over generating short-term media headlines.
